Updates are available Correction dated 2025-03-07
Click to view Correction: https://doi.org/10.1038/s44303-025-00072-4
-
Authors
Fan, Fan
Martinez, Georgia
DeSilvio, Thomas
Shin, John
Chen, Yijiang
Jacobs, Jackson
Wang, Bangchen
Ozeki, Takaya
Lafarge, Maxime W.
Koelzer, Viktor H.
Barisoni, Laura
Madabhushi, Anant
Viswanath, Satish E.
Janowczyk, Andrew
- License Information
-
More Information
Article History
Received: 18 September 2023
Accepted: 26 April 2024
First Online: 1 July 2024
Change Date: 7 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s44303-025-00072-4
Competing interests
: AM is an equity holder in Picture Health, Elucid Bioimaging, and Inspirata Inc. Currently he serves on the advisory board of Picture Health, Aiforia Inc, and SimBioSys. He also currently consults for SimBioSys. He also has sponsored research agreements with AstraZeneca, Boehringer-Ingelheim, Eli-Lilly and Bristol Myers-Squibb. His technology has been licensed to Picture Health and Elucid Bioimaging. He is also involved in three different R01 grants with Inspirata Inc. VHK has acted as an invited speaker for Sharing Progress in Cancer Care (SPCC) and Indica Labs, is on an advisory board of Takeda, and holds sponsored research agreements with Roche and IAG unrelated to the content of this study. S.V. has received sponsored research funding from Pfizer. AJ provides consulting for Merck, Lunaphore, and Roche, the latter of which he also has a sponsored research agreement. L.B. is a consultant for Sangamo and Protalix and is on the scientific advisory boards of Vertex and Nephcure.
